BMS CA224-098, RELATIVITY 098 (Melanoma)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will get relatlimab + nivolumab after surgery
-- The other group will get nivolumab on its own after surgery
- Both groups will get dosed every 4 weeks by intravenous (IV) infusion for up to 1 year
What is the Condition Being Studied?

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with stage III or 4 melanoma

- Have had their tumor(s) completely removed

For more information about who can join this study, please contact the study team at

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if combining 2 drugs (relatlimab + nivolumab) is more effective than using nivolumab on its own to prevent a recurrence of melanoma. Currently, using nivolumab on its own is the standard treatment to prevent melanoma from coming back after it has been removed by surgery.

Study Details

Full Title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Principal Investigator

Protocol Number

View on